Replies to post #778158 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

zero82,

Thanks for posting more free psychic readings 😶

You can spread rumors about NWBO, but you cannot convince anyone that “the big pharma folks” are not interested in dendritic cell technology…

Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII breast cancer trial at Roswell Park has been approved to expand in scope.. and since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…

These three scientists have coauthored several publications on dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024:
☑️ Juraj Adamik
☑️ Paul Munson
☑️ Lisa H. Butterfield


https://acir.org/weekly-digests/2023/november/metabolic-characteristics-of-dc-vaccines-define-therapy-responses

https://www.nature.com/articles/s41467-023-42881-4

https://www.nature.com/articles/s41467-022-32849-1




https://www.sciencedirect.com/science/article/abs/pii/B9780128239018000030

Adamik and Butterfield are coauthors of this publication along with several University of Pittsburgh researchers:
https://rupress.org/jem/article/217/7/e20191369/151736/Impact-of-checkpoint-blockade-on-cancer-vaccine

Pawel Kalinski at Pittsburgh and Lisa Butterfield are coauthors on this 2021 publication:
https://jitc.bmj.com/content/9/11/e003675

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456

It is notable that Roswell continues to highlight this DC technology & pembrolizumab combo study, and the source of the funding is significant too:


ASCO 2025


NCT04348747

⭐️ Trial Update Published 27 Feb 2025:

NCT04348747

The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.

☑️ Increased Patient Eligibility: A broader population now qualifies.

☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.

☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.

☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.

This trial and its interim data have been continuously peer reviewed under its grant from the U.S. DoD. The principal investigator of NCT04348747 recently joked about how rigorous and relentless peer reviewers are:

Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt

— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025

AI Fact-Checking